首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MDK |
| Uniprot No | P21741 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-143aa |
| 氨基酸序列 | VAKKKDKVKK GGPGSECAEW AWGPCTPSSK DCGVGFREGT CGAQTQRIRC RVPCNWKKEF GADCKYKFEN WGACDGGTGT KVRQGTLKKA RYNAQCQETI RVTKPCTPKT KAKAKAKKGK GKD |
| 预测分子量 | 13.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于MDK(Midkine)重组蛋白的模拟参考文献示例，基于常见研究方向整理：
---
1. **文献名称**：*Expression and Purification of Recombinant Human Midkine for Functional Studies*
**作者**：Tanaka, H. et al.
**摘要**：报道了通过大肠杆菌表达系统高效表达和纯化重组人MDK蛋白的方法，并通过细胞迁移实验验证其生物活性，证明其促进成纤维细胞增殖的能力。
2. **文献名称**：*Midkine Promotes Tumor Progression via NF-κB Signaling in Colorectal Cancer*
**作者**：Li, X. et al.
**摘要**：利用重组MDK蛋白处理结肠癌细胞，发现其通过激活NF-κB通路增强癌细胞侵袭和转移，为MDK作为癌症治疗靶点提供依据。
3. **文献名称**：*Recombinant Midkine Accelerates Peripheral Nerve Regeneration in a Rat Model*
**作者**：Yoshida, Y. et al.
**摘要**：在小鼠坐骨神经损伤模型中，局部注射重组MDK蛋白显著促进轴突再生和功能恢复，表明其在神经修复中的潜在应用价值。
---
**说明**：以上文献为模拟示例，实际引用时需以真实发表的论文为准。MDK重组蛋白的研究多集中在疾病机制(如癌症、神经损伤)和蛋白工程技术(如优化表达体系)领域。建议通过PubMed或Web of Science检索关键词“recombinant midkine”获取最新文献。
Midkine (MDK), a heparin-binding growth factor, was first identified in the early 1990s as a product of a retinoic acid-responsive gene during embryonic development. It belongs to a small family of pleiotropic growth factors, alongside pleiotrophin, characterized by their conserved cysteine-rich structure. MDK is composed of 121 amino acids, forming two distinct domains stabilized by disulfide bonds. Initially recognized for its role in embryogenesis, MDK regulates cell proliferation, migration, survival, and tissue remodeling, primarily through interactions with cell-surface receptors such as receptor-type tyrosine phosphatase ζ (RPTPζ), integrins, and low-density lipoprotein receptor-related protein-1 (LRP1). Its signaling pathways intersect with key regulators like PI3K/AKT, MAPK, and Wnt/β-catenin.
In adults, MDK expression is typically low but becomes upregulated in pathological conditions, including cancer, inflammatory diseases, and neurodegenerative disorders. In oncology, MDK promotes tumor angiogenesis, metastasis, and drug resistance, making it a biomarker and therapeutic target. Paradoxically, it also exhibits neuroprotective and tissue-repair properties, complicating its therapeutic exploitation.
Recombinant MDK production, achieved via bacterial (e.g., E. coli) or mammalian expression systems, addresses challenges in studying native MDK, such as low natural abundance and purification difficulties. Recombinant technology ensures high purity, scalability, and consistency, enabling functional studies and drug development. Applications span basic research (e.g., elucidating MDK’s role in disease mechanisms), diagnostic assays, and preclinical testing of MDK-targeted therapies, such as neutralizing antibodies or small-molecule inhibitors. However, challenges persist, including understanding MDK’s context-dependent dual roles and optimizing delivery strategies to mitigate off-target effects. Ongoing research aims to harness recombinant MDK’s potential while navigating its complex biology for therapeutic innovation.
×
